Repaglinide administration improves brachial reactivity in type 2 diabetic patients

Daniela Manzella, Rodolfo Grella, Angela Marie Abbatecola, Giuseppe Paolisso

Research output: Contribution to journalArticle

Abstract

OBJECTIVE - Several studies have demonstrated that endothelial dysfunction plays a central role in diabetic mortality and that the prooxidative effect of postprandial hyperglycemia may actively contribute to atherogenesis. Thus, we investigated the possible effect of short-acting (repaglinide) and long-acting (glibenclamide) insulin secretagogues on endothelial function in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - Sixteen type 2 diabetic patients undergoing diet treatment and with poor glucose control volunteered for the study. The study was designed as a 4-month, randomized, cross-over, parallel-group trial of repaglinide (1 mg twice a day) versus glibenclamide (5 mg twice a day). All patients underwent the following investigations: 1) anthropometries determinations, 2) blood sampling for routine laboratory analyses and for assessment of oxidative stress indexes, and 3) a brachial reactivity test to evaluate the endothelial function through the study of arterial diameter and flow changes with and without intraarterial infusion of NG-monomethyl-L-arginine, an inhibitor of nitric oxide synthase and tetraethylammonium chloride (TEA), a Ca2+-activated K+ (KCa) channel blocker. All patients were randomly assigned to receive repaglinide or glibenclamide for a period of 4 weeks. RESULTS - Repaglinide administration was associated with a significant reduction in 2-h plasma glucose levels (P <0.001) and in plasma thiobarbituric acid-reactive substances (TEARS) concentrations (P <0.001) and with a significant increase in plasma antioxidant power, assessed as Trolox equivalent antioxidant capacity (TEAC) (P <0.001), effects not observed after glibenclamide administration. With regard to brachial reactivity parameters, repaglinide but not glibenclamide was associated with a significant improvement in brachial reactivity parameters (P <0.003 for all parameters). In contrast, intra-arterial infusion of L-NMMA and TEA reduced the beneficial effect of repaglinide. CONCLUSIONS - Repaglinide administration, through good control of postprandial glucose levels, improves brachial reactivity and declines oxidative stress indexes.

Original languageEnglish
Pages (from-to)366-371
Number of pages6
JournalDiabetes Care
Volume28
Issue number2
DOIs
Publication statusPublished - Feb 2005

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Fingerprint Dive into the research topics of 'Repaglinide administration improves brachial reactivity in type 2 diabetic patients'. Together they form a unique fingerprint.

  • Cite this